PharmaJet Associates with Mundipharma to Amplify the Access of Needle-free Technology Worldwide

PharmaJet- the maker of innovative, needle-free injection technology, has joined hand with multinational healthcare company Mundipharma to advertise & distribute PharmaJet's Tropis and Stratis across 120+ marketplaces worldwide. This partnership will reinforce PharmaJet's private-to-public financing pathway. In contract, Healthios (US life sciences investment banking boutique) guides clients on placements of convertible securities conditioned upon an initial public offering on the Singapore exchange along with a pathway back to a cross-listing on Nasdaq. “Mundipharma's global network provides commercial expertise to broaden and accelerate our expansion of needle-free devices within emerging markets," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.

Both these needle-free devices Tropis (ID) and Stratis (IM/SC) are optimized for vaccine immunizations wherein Tropis delivers a superior immune response after 2 fIPV doses, and enables mass-scale fractional dose poliovirus vaccine injections at a minimum total cost than intramuscular injection. Stratis and Tropis are highly certified by regulatory bodies such as U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS to deliver medications and vaccines either intramuscularly or subcutaneously. These injectors are safe, fast and easy-to-use and eradicate needlestick injuries, needle reuse and cross contamination, thereby minimizing the sharps waste disposal.

Mundipharma is widely reckon for proposing advantage of novel treatment options to patients in areas like  such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. The company formulates successful alliances with emerging industry experts to license, market & distribute solutions with the aids of its integrated R&D-to-distribute pipeline that not only enhance patients' lives but also grant various alternatives for financially constrained healthcare systems. Mundipharma CEO, Raman Singh, said, “The main aim of associating with PharmaJET is to tender access to the distinct needle-free injection technology, to more patients particularly in the emerging world where outbreaks typically occur, and availability and cost can be a barrier to vaccinations. This includes addressing the shortage-driven need for easy-to-use, fractional dose Inactivated Poliovirus Vaccine (fIPV) intradermal delivery systems. Distributing PharmaJet's needle-free technology aligns well with our vision to deliver innovative, cost-effective, and safe solutions for the needy healthcare providers and patients”.

To further enhance the reach of needle-free technology and contribute towards the eradication of polio, PharmaJet's has signed a multi-year MoU WHO and desiring to work with health ministries with an intension to augment Polio, MMR and influenza vaccinations across the emerging world.

Read more news:

India most attractive destination for global investors: Rajnath

Sensex hits record high as GST cuts boost sentiments; banking, FMCG stocks rise